Lexeo Therapeutics, Inc. (LXEO) AI Stock Analysis
LXEO AI stock analysis summary
AI ResearchLexeo Therapeutics, Inc. (LXEO) is a clinical-stage genetic medicine company developing therapies for hereditary and acquired diseases. The company reported $0 in revenue and an EPS of -$1.02 for the trailing twelve months ended June 30, 2026. It holds a solid liquidity position with $211.7M in cash and short-term investments against $6.8M in total debt.
- Market cap
- $216.7M
- Revenue (TTM)
- $0
- P/E
- — fwd 6.4x
- 1Y return
- -69.9% S&P 500 16.8%
- Avg. target
- $20.30 668.9% vs last close
Bull case
- Lexeo holds a strong liquidity buffer with $204.9M in net cash and a current ratio of 13.89 as of June 30, 2026.
- Analyst sentiment is entirely positive with 10 Buy or Strong Buy ratings and an average price target of $20.30.
- The company's forward P/E of 6.4x trades below the US-listed Healthcare peer median of 17.3x.
Bear case
- Lexeo generated $0 in trailing twelve month revenue, and analysts forecast $0 in revenue through next fiscal year.
- The stock has declined 69.9% over the past year and trades 52.2% below its 200-day average.
- Short interest is elevated, with short percent of float recorded at 27.4%.
What Lexeo Therapeutics does
Founded in 2017 and based in New York, New York, Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing targeted genetic medicines. The company develops treatments for hereditary and acquired diseases through an advancing pipeline of gene therapies. Its lead program, LX2006, uses AAVrh10 technology to treat Friedreich's ataxia cardiomyopathy. Other cardiac pipeline assets include LX2020 for plakophilin-2 arrhythmogenic cardiomyopathy, LX2021 for DSP cardiomyopathy, and LX2022 for hypertrophic cardiomyopathy caused by the TNNI3 gene. Lexeo also develops central nervous system candidates, including LX1001, LX1020, and LX1021 for APOE4 homozygous patients, and LX1004 for CLN2 Batten disease.
Growth and profitability
Lexeo reported revenue of $518,476 in FY2020, which grew 219.6% to $1.7M in FY2021 before declining 60.5% to $654,000 in FY2022, representing a two-year revenue CAGR of 12.3%. Gross margin was 100.0% in each of those three fiscal years. As development expanded, net losses widened from -$5.2M in FY2020 to -$50.6M in FY2021 and -$59.3M in FY2022, with research and development expenses reaching $49.2M in FY2022. For the trailing twelve months ending June 30, 2026, revenue was $0, net profit margin was 0.0%, and EPS stood at -$1.02.
Balance sheet and cash flow
As of June 30, 2026, Lexeo held $211.7M in cash and short-term investments against $6.8M in total debt, resulting in net cash of $204.9M. The balance sheet reflects strong liquidity, featuring a current ratio of 13.89 and a debt-to-equity ratio of 0.03. Shareholders' equity was $235.1M and total assets were $254.9M. In FY2025, the company used $397,000 for capital expenditures and raised $80.0M through share issuance.
Valuation and performance
With a market cap of $216.7M and an enterprise value of $84.5M, Lexeo trades at a price-to-book ratio of 1.2x. Its forward P/E of 6.4x is below the 17.3x median of its US-listed Healthcare peers. The company carries a price-to-sales multiple of 478.3x, compared to the peer median of 4.1x. Over the past year, LXEO shares fell 69.9%, underperforming the S&P 500 return of 16.8%.
What analysts expect
Wall Street analysts maintain 8 Strong Buy and 2 Buy ratings on LXEO, with no Hold or Sell recommendations. The mean price target is $20.30, representing a 668.9% premium over the last close of $2.64. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$1.20 on $0 in revenue. For next fiscal year, 8 analysts estimate an EPS of -$1.37 on $0 in revenue. Lexeo beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 4, 2026.
Key risks and what to watch
- Operating cash flow remained negative in earlier years, including -$54.6M in FY2022, signaling ongoing development cash burn.
- With a beta of 1.64, the stock experiences above-average price volatility and trades near its 52-week low of $2.56.
- Ongoing operational funding required an $80.0M share issuance in FY2025, which dilutes existing shareholders.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this LXEO AI stock analysis
This page is an AI-written research summary of Lexeo Therapeutics, Inc. (LXEO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: LXEO income statement, LXEO balance sheet, LXEO key metrics, LXEO analyst forecast, LXEO chart. See the LXEO stock overview for the latest quote and news.
LXEO AI stock analysis FAQ
What programs are in Lexeo Therapeutics' clinical pipeline?
Lexeo is developing gene therapy candidates including LX2006 for Friedreich's ataxia cardiomyopathy, LX2020 for plakophilin-2 arrhythmogenic cardiomyopathy, LX2021, LX2022, LX1004 for CLN2 Batten disease, and LX1001, LX1020, and LX1021 for APOE4 homozygous conditions.
What is Lexeo Therapeutics' current cash position?
As of June 30, 2026, Lexeo held $211.7M in cash and short-term investments alongside $6.8M in total debt, providing $204.9M in net cash.
Does Lexeo Therapeutics pay a dividend?
No, Lexeo Therapeutics does not pay a dividend. The company directs its capital toward advancing its clinical-stage pipeline.
What do Wall Street analysts forecast for LXEO stock?
Analysts have an average price target of $20.30 for LXEO, representing an upside of 668.9% over the last close of $2.64, with all 10 tracked analysts rating it a Buy or Strong Buy.